US Patent

US10420749 — Crystalline form of lorlatinib free base

Method of Use · Assigned to Pfizer Inc · Expires 2036-07-27 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a crystalline form of the drug lorlatinib free base, known as Form 7, used in treating abnormal cell growth, such as cancer, in mammals.

USPTO Abstract

This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.

Drugs covered by this patent

Lorbrena (lorlatinib) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2633`	—	Lorbrena
`U-2633`	—	Lorbrena

Patent Metadata

Patent number: US10420749
Jurisdiction: US
Classification: Method of Use
Expires: 2036-07-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.